Nynomic AG (ETR:M7U)
Germany · Delayed Price · Currency is EUR | Market Cap | 107.07M +6.5% |
| Revenue (ttm) | 93.16M -18.2% |
| Net Income | -704.00K |
| EPS | -0.11 |
| Shares Out | 6.57M |
| PE Ratio | n/a |
| Forward PE | 23.12 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,616 |
| Open | 15.75 |
| Previous Close | 15.60 |
| Day's Range | 15.75 - 16.60 |
| 52-Week Range | 8.22 - 26.30 |
| Beta | 1.07 |
| Analysts | Strong Buy |
| Price Target | 26.00 (+59.51%) |
| Earnings Date | Aug 12, 2026 |
About Nynomic AG
Nynomic AG, together with its subsidiaries, manufactures and sells products for permanent, non-contact, and non-destructive optical measurement technology. The company also supplies customized system solutions in the areas of control engineering, sensor technology, and laboratory automation or spectrometry; components and systems for industrial optical spectroscopy, including UV-VIS-NIR and Raman diode array spectroscopy with associated software solutions; and develops and manufactures optical measurement systems for various applications. In ad... [Read more]
Financial Performance
In 2025, Nynomic AG's revenue was 93.16 million, a decrease of -9.76% compared to the previous year's 103.24 million. Losses were -704,000, 9.49% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for M7U stock is "Strong Buy." The 12-month stock price target is €26.00, which is an increase of 59.51% from the latest price.
News
FY25 prelims: Leaving the trough behind: Nynomic's FY25 results showed revenue decline but Q4 strength ...
Nynomic released its preliminary FY25 figures, meeting the lower ends of the updated guidance but more importantly providing a FY26 guidance signalling an inflection towards profitable growth follo...
FY25 prelims: Leaving the trough behind
Nynomic's FY25 results showed revenue decline but Q4 strength signals recovery. FY26 guidance suggests profitable growth, driven by Pharma and Semiconductor demand. Maintain BUY, € 21 PT.
Q3 prelims: Nynomic should have passed the trough; chg. est.
Nynomic's Q3 results show mixed performance with improved order intake and positive EBIT, but FY25 sales guidance trimmed. From 2026 onwards efficiency measures should boost margins. Jetzt den vollstä...
Muted start into the year; gradual improvements expected
Nynomic published a muted start into FY25, largely the result of the ongoing uncertainty within its key end markets. Yet, management remains confident to be able to record gradual improvements through...
Q4 prelims in line, returning to growth in FY25; chg. est.
Nynomic released Q4 prelims largely in line with expectations and a FY25 guidance, which reflects a return to growth. Yet, the expected FY25 growth guidance fell short of market expectations due to on...
Muted prel. Q3 in line with expectations // guidance confirmed
Nynomic released muted preliminary Q3 results in line with our expectations. Key drivers were delayed product call-offs and certain budget-related project postponements into FY25e. Jetzt den vollständ...
H2 marked by postponements, bright mid-term prospects; chg
Nynomic cut its FY24 guidance due to delayed order intakes and project postponements but should return to strong growth from FY25 onwards as reflected by the confirmed mid-term guidance. Jetzt den vol...